ECC 5004
Alternative Names: ECC-5004Latest Information Update: 11 Mar 2024
At a glance
- Originator AstraZeneca; Eccogene
- Developer Eccogene
- Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies; Small molecules
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus